Clinigen Sustainability Profile
Clinigen Group plc, headquartered in the United Kingdom, is a leading global pharmaceutical and services company specialising in the provision of access to medicines. Founded in 2010, Clinigen has rapidly established itself in the healthcare industry, focusing on unlicensed and niche products, clinical trial services, and the management of complex supply chains. With a strong presence in Europe, North America, and Asia, Clinigen offers unique solutions that bridge the gap between pharmaceutical companies and patients. Their core services include the provision of clinical trial supplies and the management of access programmes, ensuring that patients receive critical treatments when they need them most. Clinigen's commitment to patient access and innovative solutions has positioned it as a trusted partner in the global healthcare landscape, achieving significant milestones in expanding its product offerings and market reach.
DitchCarbon Score
How does Clinigen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Clinigen's score of 60 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Clinigen's reported carbon emissions
In 2022, Clinigen Limited reported total carbon emissions of approximately 72,050,000 kg CO2e, comprising 44,600,000 kg CO2e from Scope 1, 2,900,000 kg CO2e from Scope 2, and 24,550,000 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions included 250,000 kg CO2e from business travel and 2,400,000 kg CO2e from waste generated in operations. Clinigen has set ambitious climate commitments, aiming for a 42% reduction in absolute Scope 1 and 2 greenhouse gas emissions by FY2030, using FY2023 as the base year. This target is mirrored for Scope 3 emissions, which also aims for a 42% reduction within the same timeframe. Furthermore, Clinigen has established a long-term goal to achieve a 90% reduction in absolute emissions across all scopes by FY2040. The company has committed to reaching net-zero greenhouse gas emissions across its value chain by FY2040, aligning its targets with the Science Based Targets initiative (SBTi) to ensure they are consistent with the reductions required to limit global warming to 1.5°C. These commitments reflect Clinigen's proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical sector.
How Carbon Intensive is Clinigen's Industry?
How Carbon Intensive is Clinigen's Location?
Clinigen's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Clinigen has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Boehringer Ingelheim Pharmaceuticals, Inc.
Fresenius
Frequently Asked Questions
Common questions about Clinigen's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.